Evolve BioSystems, Inc. is the manufacturer of Evivo®, a proprietary groundbreaking probiotic proven to resolve Newborn Gut Deficiency, proven by several studies to affect more than 90% of babies in the U.S.. Evivo contains activated B. infantis EVC001, which restores bacteria essential to the infant gut and guides critical development of infants’ digestive and immune systems. Evivo works by favorably altering the gut’s biochemistry to reduce potentially pathogenic bacteria by 80 percent, which in turn significantly reduces intestinal inflammation. Those pathogens and their ensuing inflammations have been statistically linked to a significantly higher risk of both short- and long-term health issues including colic, diaper rash, eczema, asthma, allergies and even Type 1 Diabetes.
Martino Verga, CEO Sacco System: “We are impressed by the science that Evolve has developped, and are excited to be among Evolve’s European investors. We believe in Evolve’s core mission as our very own company, CSL, was the first company in Italy to ever study Lactic Acid Bacteria for human health.
One of Sacco System’s pillars is creative intelligence, with a focus on R&D and innovation. For this reason, we are naturally proud to be partners with Evolve, a company dedicated to developing the next generation of probiotics to improve life and wellbeing.
We strongly trust that there is always a probiotic that will make your life better”.
Sacco System, with its reputation as a highly professional manufacturer of probiotics and other live biotherapeutics, will support Evolve BioSystems Inc with an investment finalized to eventually bring Evivo® Baby Probiotic to Europe.
Tim Brown, CEO Evolve BioSystems, Inc.: “We are pleased to add Sacco to the growing list of investors in Evolve” said Tim Brown, CEO of Evolve BioSystems, “This investment from a major Italian corporation signals the interest in Evolve’s proprietary product lines on a global Basis”.
About Sacco System
Sacco System is an international biotech holding operating in the food, nutraceutical, and pharmaceutical industries. A unique network of four biotechnology companies working in synergy within a single business system, built on tradition, expertise, research & innovation.
Starting from important expertise in enzymes and in cultures 150 years ago, today we focus also on probiotic manufacturing, research and development for nutraceutical and pharmaceutical fields.
About Evolve BioSystems, Inc.
Evolve BioSystems, Inc. is a privately-held leading microbiome company in the U.S., dedicated to discovering and implementing solutions that improve the short and long-term health of infants worldwide. Launched at the University of California, Davis, following more than a decade of pioneering research at the Foods for Health Institute, Evolve has progressively built substantial science and technology assets, focused on the nutrition, biochemistry, and physiology sides of the developing infant gut microbiome. The Company’s breakthrough research shows that nine out of ten U.S. infants are suffering from Newborn Gut Deficiency, a dramatic shortage of protective bacteria in the infant gut microbiome that is associated with enteric inflammation, disruption of stool patterns, diaper rash, colic, and fussiness. The Company’s revolutionary product Evivo, has been shown to successfully address these and other conditions in both term and preterm infants. Together with clinical research partners worldwide, Evolve is on a mission to establish B. infantis EVC001 as the standard-of-care for all infants – for a better life-long health trajectory. Evolve is a portfolio company of Horizons Ventures, Cargill, Manna Tree Partners, The Bill & Melinda Gates Foundation, and Johnson &Johnson Development Corporation.
